Drug Profile
GTX 103
Alternative Names: GTX-103Latest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Grace Therapeutics
- Developer Acasti Pharma
- Class Vascular disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Vascular disorders
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Vascular-disorders in USA
- 27 Aug 2021 Grace Therapeutics has been acquired and merged into Acasti Pharma
- 02 Apr 2018 Preclinical trials in Vascular disorders (aortic aneurysm) in USA (unspecified route) (Grace Therapeutics pipeline, April 2018)